SNES SenesTech: שווי פעילות לרווח לפני ריבית, מסים ופחת
The market dynamics reflected in the quotes on GURU.Markets for SenesTech, Inc. (SNES) show an EV/EBITDA of 0.00. SenesTech, Inc. (SNES) generates revenue through eco-friendly rodent population control by promoting its innovative drug, ContraPest. High production efficiency is achieved via automated chemical plants utilizing robotics. Business stability is guaranteed by a staff of experienced biologists and the precise selection of corporate sales development specialists.
פילוחים אנליטיים של חברת senestech.com (SNES)
This indicator calculates the ratio of total enterprise value, including net debt, to earnings before interest, taxes, depreciation, and amortization, determining the payback period for all assets. For SenesTech, Inc. (SNES), whose stability depends on the expansion of a single product within the agricultural sector, the current EV/EBITDA ratio with debt reflects the market's real-time assessment of single-product dependency risks and the pace of business scaling.
